Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Schwabe

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|August 26, 2020
A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy ParticipantsSheng Feng, Edward Gane, Christian Schwabe, et al.
Experimental Biology and Medicine (Maywood, N.J.)|January 14, 2003
Abnormal relaxin secretion during pregnancy in women with type 1 diabetesPaul G Whittaker, J R G Edwards, Carla Randolph, et al.
Antiviral Therapy|November 21, 2025
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participantsEd Gane, Christian Schwabe, Min Wu, et al.
Pharmacology Research & Perspectives|April 26, 2020
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta<sup>®</sup> in healthy subjects: A randomized, double-blind trialChris Wynne, Christian Schwabe, Emmanuelle Vincent, et al.
Expert Review of Clinical Immunology|March 31, 2022
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trialChristian Schwabe, Andras Illes, Martin Ullmann, et al.
Biochemistry|December 17, 2008
Solution structure of a conformationally restricted fully active derivative of the human relaxin-like factorErika E Büllesbach, Mathias A S Hass, Malene R Jensen, et al.
Biology of Reproduction|June 17, 2005
Early placental insulin-like protein (INSL4 or EPIL) in placental and fetal membrane growthLynnae Millar, Nicole Streiner, Lisa Webster, et al.
Journal of Hepatology|July 16, 2019
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot studyEdward Gane, Daniel J Verdon, Anna E Brooks, et al.
Expert Opinion on Biological Therapy|October 5, 2022
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adultsChristopher Wynne, Christian Schwabe, Heimo Stroissnig, et al.
Hepatology (Baltimore, Md.)|August 3, 2018
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without CirrhosisEdward J Gane, Catherine A Stedman, Christian Schwabe, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|August 26, 2020
A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy ParticipantsSheng Feng, Edward Gane, Christian Schwabe, et al.
Experimental Biology and Medicine (Maywood, N.J.)|January 14, 2003
Abnormal relaxin secretion during pregnancy in women with type 1 diabetesPaul G Whittaker, J R G Edwards, Carla Randolph, et al.
Antiviral Therapy|November 21, 2025
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participantsEd Gane, Christian Schwabe, Min Wu, et al.
Pharmacology Research & Perspectives|April 26, 2020
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta<sup>®</sup> in healthy subjects: A randomized, double-blind trialChris Wynne, Christian Schwabe, Emmanuelle Vincent, et al.
Expert Review of Clinical Immunology|March 31, 2022
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trialChristian Schwabe, Andras Illes, Martin Ullmann, et al.
Biochemistry|December 17, 2008
Solution structure of a conformationally restricted fully active derivative of the human relaxin-like factorErika E Büllesbach, Mathias A S Hass, Malene R Jensen, et al.
Biology of Reproduction|June 17, 2005
Early placental insulin-like protein (INSL4 or EPIL) in placental and fetal membrane growthLynnae Millar, Nicole Streiner, Lisa Webster, et al.
Journal of Hepatology|July 16, 2019
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot studyEdward Gane, Daniel J Verdon, Anna E Brooks, et al.
Expert Opinion on Biological Therapy|October 5, 2022
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adultsChristopher Wynne, Christian Schwabe, Heimo Stroissnig, et al.
Hepatology (Baltimore, Md.)|August 3, 2018
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without CirrhosisEdward J Gane, Catherine A Stedman, Christian Schwabe, et al.
Pageof 6